San Diego Biotech CEO Charged With $33M Clinical Trial Data Fraud
Risk Signal Summary
A biotech CEO falsified clinical trial results for a cancer treatment drug to raise $33M in investor funding, while the FDA found the underlying data to be fabricated.
Why This Matters
Governance and compliance anomalies in organizations managing public funds or charitable assets directly affect donors, beneficiaries, and taxpayers. The risk indicators identified in this report warrant further scrutiny by regulators, donors, and oversight bodies.
Create a free account
Unlimited access to all articles · No daily limit
No credit card · Instant access
Multiple related entities detected
🔒 Meridian Biopharma Inc. has potential risk indicators with connected organizations. Unlock full network analysis.
Sign up free to unlock →Disclaimer: This report identifies risk indicators and unusual financial patterns based on publicly available IRS Form 990 data and government enforcement records. It does not assert fraud, criminal conduct, or legal violations. All findings are for informational purposes only and should not be construed as legal or financial advice.
Share this finding
Post text is pre-formatted for maximum reach — you can edit before posting.
Discover more risk signals across the USA.